A randomized, exploratory molecular imaging study targeting amyloid β with a novel 8-OH quinoline in Alzheimer's disease: The PBT2-204 IMAGINE study.

Alzheimers Dement (N Y) · 2017 · PMC5702880 · PMID 29201996

Europe PMC DOI

hedged sentences

—

closest p

—

boldest claim

The sentences

highly significantno p-value reported

In the 27 subjects who did complete both phases of this study, the PBT2 group showed a highly significant fall in the first 12 months ( Fig. 7 ), coming off a baseline value of 2.42 ± 0.51.

also in 132,142 other papers

a nonsignificant trendno p-value reported

The effect of PBT2 on brain MRI volumetrics There was a nonsignificant trend for a slower rate of change in hippocampal atrophy to be slower in the PBT2 group (−0.029 cc/yr) compared to the placebo group (−0.057 cc/yr) over the double-blind phase.

also in 5,406 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.